Colorectal cancer is the third most common cancer in the world with increasing incidence
and mortality rates globally. Standard treatments for colorectal cancer have always been …

Treatment of young adults with colorectal cancer (CRC) represents an unmet clinical need,
especially as diagnosis in this population might lead to the greatest loss of years of life …

Background Pembrolizumab has shown improved progression-free survival versus
chemotherapy in patients with newly diagnosed microsatellite instability-high or mismatch …

Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …

Background HER2 amplification has been identified in 2–3% of patients with colorectal
cancer, although there are currently no approved HER2-targeted therapies for colorectal …

Abstract Background Programmed death 1 (PD-1) blockade has clinical benefit in
microsatellite-instability–high (MSI-H) or mismatch-repair–deficient (dMMR) tumors after …

The number of deaths from colorectal cancer in Japan continues to increase. Colorectal
cancer deaths exceeded 50,000 in 2016. In the 2019 edition, revision of all aspects of …

PURPOSE BRAF V600E mutations are rarely associated with objective responses to the
BRAF inhibitor vemurafenib in patients with metastatic colorectal cancer (CRC). Blockade of …

PURPOSE A proper estimation of the magnitude of the overall survival (OS) benefit from
infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus …

Abstract DESTINY-CRC01 (NCT03384940) was a multicenter, open-label, phase 2 trial
assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2 …